HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.
Gastroenterology
RCT
Ketotifen shows significant improvements in hepatic steatosis and fibrosis indices compared with vitamin E in a pilot study of NAFLD.
Ketotifen beats Vitamin E for fatty liver disease in new trial
This randomized pilot study enrolled 60 individuals with non-alcoholic fatty liver disease (NAFLD) and followed them for 6.0 months. Partici…
New research shows a common allergy medicine reduces liver fat and scarring more effectively than Vitamin E for people with fatty liver dise…
Apr 27, 2026
Drug Pipeline
Sys. Review
Narrative review examines antioxidant metabolites for autism spectrum disorder in children
Could antioxidant nutrients help children with autism spectrum disorder?
This narrative review evaluates the potential role of antioxidant metabolites from botanical drugs and nutrients, including vitamins E and C…
Antioxidant nutrients like vitamins E and C, plus botanical compounds, may help address oxidative stress linked to autism spectrum disorder …
Frontiers
Apr 19, 2026
Orthopedics & Sports Medicine
Sys. Review
Oxidative stress drives steroid-induced necrosis of femoral head; antioxidants may help maintain redox balance.
Why Steroid Pills Can Quietly Starve Your Hip Bone
This systematic review examined the role of oxidative stress and various antioxidant classes in steroid-induced necrosis of the femoral head…
Steroid pills used for asthma and lupus may quietly starve hip bones of blood through oxidative stress, potentially leading to bone death an…
Frontiers
Apr 13, 2026
Gastroenterology
Phase II
Phase 2 trial tests three Vitamin E doses versus placebo in 200 adults with NAFLD
Vitamin E dosing study in 200 adults with fatty liver disease completes trial
A phase 2 randomized controlled trial enrolled 200 adults with NAFLD to compare three doses of Vitamin E (200 IU, 400 IU, 800 IU) with place…
A completed trial on Vitamin E for fatty liver disease has finished, but the results showing if the doses helped or caused harm are not yet …
CT.gov
Mar 30, 2026